Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Further Reading

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

9 Dec 2009
Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

8 Dec 2009
Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

8 Dec 2009
Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

8 Dec 2009
Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

8 Dec 2009
Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

7 Dec 2009
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting

Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting

7 Dec 2009
Synta Pharmaceuticals announces study results of elesclomol

Synta Pharmaceuticals announces study results of elesclomol

7 Dec 2009
New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

2 Dec 2009
University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

2 Dec 2009
Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

25 Nov 2009
Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

18 Nov 2009
AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

17 Nov 2009
Two units of UCB reduce risk of leukemia from returning, shows new study

Two units of UCB reduce risk of leukemia from returning, shows new study

16 Nov 2009
EpiCept announces third quarter 2009 financial results

EpiCept announces third quarter 2009 financial results

10 Nov 2009
Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

9 Nov 2009
FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

6 Nov 2009
Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

6 Nov 2009
EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

3 Nov 2009
Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

3 Nov 2009

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback